Belgian biopharmaceutical company Flen Health has selected AGC Biologics as their CDMO partner to provide process development, scale-up, and GMP manufacturing services for a new and improved wound and ...

Why is a drug that is available in the United States not available in Japan?Doctor, that medicine is already being used in ...

As of September 16, 2026, BlossomHill Therapeutics had 31,784,909 shares of common stock issued, each with a par value of ...

Policy Background of Participation in Project Orbis and the Transformation of Oncology Drug Regulatory ReviewThe formal ...

During Q2 2026, the Harbor AI Inflection Strategy ETF returned 40.75%, outperforming its benchmark. Read the full commentary ...

The average one-year price target for Fortress Biotech, Inc. - Preferred Stock (NASDAQCM:FBIOP) has been revised to $37.34 / share. This is an increase of 10.56% from the prior estimate of $33.77 ...

In April, she found out that the University was changing undergraduate classification for Progressive Degree Program students ...

Liminal Biosciences stock (ISIN CA53272L1031) currently has no newly surfaced, verifiable price quote or fresh fundamental ...

The average one-year price target for Oramed Pharmaceuticals (NASDAQCM:ORMP) has been revised to $7.14 / share. This is an increase of 12.00% from the prior estimate of $6.38 dated August 25, 2026.

Clinical data harmonization is the real bottleneck standing between life sciences companies and AI's transformative potential. The life sciences industry is navigating a pivotal transition in 2026.

EMA committee recommends approval of Alexion’s Klygefa to treat adults with generalised myasthenia gravis: Cambridge, UK Monday, September 21, 2026, 10:00 Hrs [IST] Alexion, Ast ...